Affitech Appoints New Board Member.Direvo Chief Executive Dr. Thomas von Ruden Joins Affitech Supervisory Board Supervisory board The board of directors that represents stakeholders in the governance of the corporation. OSLO, Norway -- The human antibody company, Affitech AS, announced today the appointment of Dr. Thomas von Ruden, currently the Chief Executive Officer of Cologne, Germany-based Direvo Biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. AG as a Member of its Supervisory Board. With more than 14 years of experience in the pharmaceutical and biotechnology industry including human antibody area, Dr. von Ruden took his current position as the Chief Executive Officer of Direvo in April 2006 from the Vienna-based Institute for Medical Genome Research Genome Research is the title of a peer-reviewed scientific journal published by Cold Spring Harbor Laboratory Press. The focus of the journal is on genome-wide studies in any organism, including single gene studies that are placed in a genomic context. . Previously, he was the Chief Scientific Officer and Executive VP Business Development with MorphoSys AG, the Germany-based antibody company in Munich for six years. After an academic career at the European Laboratory of Molecular Biology The Laboratory of Molecular Biology (or LMB) is a research institute in Cambridge, England, which was at the forefront of the revolution in molecular biology which occurred in the 1950-60s. Since then it remains a major medical research laboratory with a much broader focus. , Heidelberg, and the Institute of Molecular Pathology Molecular pathology is an emerging discipline within pathology which is focused on the use of nucleic acid-based techniques such as DNA sequencing, fluorescent in-situ hybridization, reverse-transcriptase polymerase chain reaction, and nucleic acid microarrays for specialised studies of , Vienna, Dr von Ruden joined Boehringer Ingelheim in Vienna, where he was appointed Director of Molecular Biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller and was responsible for drug discovery in oncology. He holds several advisory board positions in biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. and public research organisations. "I am indeed honored to be appointed to the Company's Board of Directors," said Dr von Ruden. "Affitech is a unique antibody company, possessing not only proven target identification technologies in the area of oncology, but also a proprietary antibody generation platform. They have several antibody product candidates in development and have built quite a few business collaborations with leading biotechnology and pharma companies. The combination of these elements positions the company well for its continued development. Affitech's outlook is very promising, and I look forward to contributing to the future direction of the company." Welcoming the appointment Dr. Martin Welschof, Chief Executive Officer of Affitech commented: "We are delighted about Dr. von Ruden's joining of our Board of Directors at the current exciting phase of the Company's growth. We now have collaborations with leading antibody players including Roche, Xoma, Viventia and Peregrine. In addition we have consolidated our IP position by in licensing and leveraging our key Breitling IP and have put several product candidates in the preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. development pipeline. We have already been building up both our management and scientific teams in order to accelerate development of our product candidates, as well as those of our partners. The appointment of Thomas to the Board will bring further invaluable experience and industry contacts as we strive for continued success in the antibody landscape." Editors notes Affitech AS is a privately held human therapeutic antibody company with headquarters and R&D facilities in Oslo, Norway and US subsidiary in the San Francisco Bay Area “Bay Area” redirects here. For other uses, see Bay Area (disambiguation). The San Francisco Bay Area, colloquially known as the Bay Area or The Bay . The current disease focus is oncology, and deals include Roche, Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, Pharmexa and others. www.affitech.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion